The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Phase III Randomized Controlled Trial Comparing the Survival of Patients With Unresectable Hepatocellular Carcinoma Treated With Nolatrexed or Doxorubicin
Abstract
Purpose: The study objective was to compare the overall survival (OS) of patients with unresectable or metastatic hepatocellular carcinoma (HCC) treated with nolatrexed (NOL) or doxorubicin (DOX). Patients and Methods: Patients from North America, Europe, and South Africa (N = 445) with HCC were randomly assigned to receive NOL or DOX. Eligible patients had Karnofsky performance status (KPS) ≥ 60%, Cancer of the Liver Italian Program (CLIP) score ≤ 3, and adequate organ function. Primary end point was OS. Secondary end points included progression-free survival (PFS), objective response rates, and safety. The treatment groups were well-balanced with regards to age, sex, ethnic origin, and underlying liver disease. Randomization was stratified according to KPS and CLIP score. Results: At the time of the final analysis, 377 patients had died. Median OS was 22.3 weeks for NOL and 32.3 weeks for DOX (P = .0068). The hazard ratio was 0.753 in favor of DOX. Objective response rate (complete response [CR] plus partial response [PR]) was 1.4% for NOL and 4.0% for DOX. Median PFS was 12 weeks for NOL and 10 weeks for DOX (P = .7091). Median time to treatment failure was 8.4 weeks for NOL and 9.1 weeks for DOX (P = .0969). Grade 3 and 4 stomatitis, vomiting, diarrhea, and thrombocytopenia were more common in the NOL arm. Alopecia was more common in the DOX arm. More patients were withdrawn from study for toxicity in the NOL arm than in the DOX arm. Conclusion: NOL showed minimal activity in this phase III trial. Further exploration at this dose and schedule in HCC is not warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,196
Epidemiology of Hepatocellular Carcinoma
Bosch, F. X., Ribes, J., Cléries, R., & Díaz, M. (2005) · Clinics in Liver Disease · doi:10.1016/j.cld.2004.12.009 · Cited by 1,131
Barbara, L., Benzi, G., Gaiani, S., Fusconi, F., Zironi, G., Siringo, S., Rigamonti, A., Barbara, C., Grigioni, W., Mazziotti, A., et al. (1992) · Hepatology · doi:10.1002/hep.1840160122 · Cited by 431
Digestive and liver diseases statistics, 2004
Russo, M. W., Wei, J. T., Thiny, M. T., Gangarosa, L. M., Brown, A., Ringel, Y., Shaheen, N. J., & Sandler, R. S. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.01.025 · Cited by 335
Viral hepatitis and hepatocellular carcinoma
Michielsen, P. P., Francque, S. M., & van Dongen, J. L. (2005) · World Journal of Surgical Oncology · doi:10.1186/1477-7819-3-27 · Cited by 181
Natural History of Untreated Primary Hepatocellular Carcinoma: A Retrospective Study of 157 Patients
Pawarode, A., Voravud, N., Sriuranpong, V., Kullavanijaya, P., & Patt, Y. Z. (1998) · American Journal of Clinical Oncology · doi:10.1097/00000421-199808000-00014 · Cited by 174
Asymptomatic hepatocellular carcinoma in Child's A cirrhosis
Cottone, M., Virdone, R., Fusco, G., et al. (1989) · Gastroenterology · doi:10.1016/0016-5085(89)90528-3 · Cited by 116
Carpenter, J. T., Roche, H. H., Campone, M., Colomer, R., Jagiełło-Gruszfeld, A., Moore, L., D’Amore, M., Kong, S., Boni, J. P., & Baselga, J. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.564 · Cited by 99
Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma
Lee, J., Park, J. O., Kim, W. S., Park, S. H., Park, K. W., Choi, M. S., Lee, J. H., Koh, K. C., Paik, S. W., Yoo, B. C., et al. (2004) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-004-0837-7 · Cited by 83
Cited by
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Escudier, B., Porta, C., Schmidinger, M., Algaba, F., Patard, J. J., Khoo, V., Eisen, T., & Horwich, A. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu259 · Cited by 2,251
Self-citationLammer, J., Malagari, K., Vogl, T., Pilleul, F., Denys, A., Watkinson, A., Pitton, M., Sergent, G., Pfammatter, T., Terraz, S., et al. (2010) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-009-9711-7 · Cited by 1,557
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
(2012) · European Journal of Cancer · doi:10.1016/j.ejca.2011.12.021 · Cited by 1,096
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Vogel, A., Cervantes, A., Chau, I., Daniele, B., Llovet, J. M., Meyer, T., Nault, J. C., Neumann, U., Ricke, J., Sangro, B., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy308 · Cited by 1,048
Omata, M., Lesmana, L. A., Tateishi, R., Chen, P.-J., Lin, S.-M., Yoshida, H., Kudo, M., Lee, J. M., Choi, B. I., Poon, R. T. P., et al. (2010) · Hepatology International · doi:10.1007/s12072-010-9165-7 · Cited by 1,026
Novel advancements in the management of hepatocellular carcinoma in 2008
Llovet, J. M., & Bruix, J. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.01.022 · Cited by 815
Gao, Q., Wang, X.-Y., Qiu, S.-J., Yamato, I., Sho, M., Nakajima, Y., Zhou, J., Li, B.-Z., Shi, Y.-H., Xiao, Y.-S., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1608 · Cited by 813
Loblaw, D. A., Virgo, K. S., Nam, R., Somerfield, M. R., Ben-Josef, E., Mendelson, D. S., Middleton, R., Sharp, S. A., Smith, T. J., Talcott, J., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.1949 · Cited by 555
Treatment of intermediate-stage hepatocellular carcinoma
Forner, A., Gilabert, M., Bruix, J., & Raoul, J.-L. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.122 · Cited by 466
Hepatocellular Carcinoma: Current Management and Perspectives for the Future
Rahbari, N. N., Mehrabi, A., Mollberg, N. M., Müller, S. A., Koch, M., Büchler, M. W., & Weitz, J. (2011) · Annals of Surgery · doi:10.1097/sla.0b013e31820d944f · Cited by 453
Yeung, O. W. H., Lo, C.-M., Ling, C.-C., Qi, X., Geng, W., Li, C.-X., Ng, K. T. P., Forbes, S. J., Guan, X.-Y., Poon, R. T. P., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.10.029 · Cited by 453
Abou-Alfa, G. K., Johnson, P., Knox, J. J., Capanu, M., Davidenko, I., Lacava, J., Leung, T., Gansukh, B., & Saltz, L. B. (2010) · JAMA · doi:10.1001/jama.2010.1672 · Cited by 448
Self-citationAntifolates in cancer therapy: Structure, activity and mechanisms of drug resistance
Gonen, N., & Assaraf, Y. G. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.07.002 · Cited by 437
Hepatocellular carcinoma (HCC): beyond sorafenib—chemotherapy
Kim, D. W., Talati, C., & Kim, R. (2017) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2016.09.07 · Cited by 333
Metadata
- Authors
- Gish, R. G., Porta, C., Lazar, L., Ruff, P., Feld, R., Croitoru, A., Feun, L., Jeziorski, K., Leighton, J., Knox, J., Gallo, J., & Kennealey, G. T.
- Venue
- Journal of Clinical Oncology
- Published
- 2007-07-20
- Volume
- 25
- Issue
- 21
- Pages
- 3069-3075
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2111077571
- Cited by
- 279
- References
- 17
- FWCI
- 12.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.